These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20921291)

  • 1. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
    Pierce D; Hossack S; Poole L; Robinson A; Van Heusen H; Martin P; Smyth M
    Nephrol Dial Transplant; 2011 May; 26(5):1615-21. PubMed ID: 20921291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
    Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
    Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of the phosphate binder, lanthanum carbonate.
    Damment SJ
    Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
    Coppolino G; Lucisano S; Rivoli L; Fuiano G; Villari A; Villari I; Leonello G; Lacquaniti A; Santoro D; Buemi M
    Ther Apher Dial; 2015 Oct; 19(5):471-6. PubMed ID: 25866250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of efficient phosphate binding on bone in chronic renal failure rats.
    Behets GJ; Gritters M; Dams G; De Broe ME; D'Haese PC
    Ren Fail; 2005; 27(4):475-84. PubMed ID: 16060138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
    Ginsberg C; Zelnick LR; Block GA; Chertow GM; Chonchol M; Hoofnagle A; Kestenbaum B; de Boer IH
    Nephrol Dial Transplant; 2020 Apr; 35(4):616-623. PubMed ID: 32160298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease-A Comparative Clinical Study.
    Nain P; Nayak N; Maj MC; Singh RK; Kaur J; Jeong Y; Maity S; Nath R; Hilgers RH; Nauhria S; Nauhria S
    Pharmacy (Basel); 2023 Feb; 11(1):. PubMed ID: 36827665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
    Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
    Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer carbonate.
    Barna MM; Kapoian T; O'Mara NB
    Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.
    Gray NA; Krishnasamy R; Vardesh DL; Hollett PR; Anstey CM
    Nephrology (Carlton); 2011 Nov; 16(8):688-96. PubMed ID: 21649793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
    Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
    Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
    Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
    Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.